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End-stage renal disease (ESRD) may be defined 
as a state of renal insufficiency of such severity that 
the affected individual is unable to carry out his usual 
activities because of symptoms usually attributed to 
the uremic syndrome. This state has been reached, or 
is imminent, when the serum creatinine concentration 
rises above 10 mg/ 100 ml and/or the creatinine clear-
ance falls below 5 to 10 ml/min and reversible causes 
of renal failure such as obstructive uropathy, bilateral 
renal vascular disease, severe accelerated hyper-
tension, hypercalcemic nephropathy, uric acid ne-
phropathy, and certain immunologic diseases such as 
Wegener granulomatosis have been excluded. Pro-
spective analysis of a population of patients meeting 
these biochemical criteria has clearly shown that at 
least 80% will require dialysis within 150 days and 
40% will require this method of treatment within 60 
days to sustain life. 1 Thus, when ESRD is reached, 
weighty decisions concerning the patient's care must 
be made. It is the purpose of this paper to review the 
management of ESRD and to point out some of the 
problems which may complicate the several therapeu-
tic modalities. 
The alternative methods of management of the 
patient with ESRD are dialysis and transplantation . 
These two therapeutic modalities are by no means 
mutually exclusive and, as we shall see, should be 
considered complementary. However, virtually all 
patients must undergo a period of dialysis, even those 
awaiting transplantation. Therefore, dialysis is the 
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first mode of treatment encountered by a patient 
entering an ESRD program. 
At the present time there are few absolute con-
traindications to entrance into an ESRD program for 
dialysis and transplantation. However, patients with 
uncontrolled psychotic behavior, extreme old age, 
advanced artherosclerotic vascular disease, or dis-
seminated malignancy are probably not candidates 
for therapy. 
Principles of good conservative management of 
renal failure such as restriction of dietary protein, 
careful attention to fluid and electrolyte balance with 
tailoring of dietary sodium intake to the obligatory 
sodium loss, and the administration of sodium bi-
carbonate supplements and oral phosphate binders 
where appropriate may postpone the absolute need 
for dialysis or transplantation if introduced when the 
patient has moderately severe renal insufficiency. Re-
cent studies have demonstrated that the period of 
conservative management can be prolonged even fur-
ther by the administration of a special mixture of the 
keto-analogues of the essential amino acids.2 This 
maneuver allows for the dietary administration of 
very limited quanti ties of nitrogen and is predicated 
on the assumption that some of the urea nitrogen will 
be recycled into the synthesis of essential as well as 
nonessential amino acids. Unfortunately, these keto-
acids are not commercially available at present, but 
perhaps will be in the future. 
Survival rates for patients treated by hemo-
dialysis at home and those who have received a well-
matched transplant from a living related donor are 
both greater than 80% at two years.3 It is worth 
noting, however, that this represents patient survival 
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and not graft survival which is only about 70%, thus 
indicating that some 10% to 15% of the transplant 
recipients who survive two years have suffered an 
undetermined amount of morbidity in association 
with rejection of their graft. Survival with in-center 
dialysis and cadaver transplantation is less good, with 
a two-year survival rate of approximately 70% in each 
case.3 The two-year graft survival in patients with 
cadaver transplants is less than 50%. These statistics 
suggest the desirability of home dialysis and living 
related donor transplantation, but do not demon-
strate a clear superiority of in-center dialysis or cada-
ver transplantation. Thus, factors other than survival 
must be considered in selecting a mode of therapy. 
Age is a major factor which may influence thera-
peutic selection . Children and adolescents tend to 
have diminished growth and maturation while on 
dialysis4 and they frequently rebel against the rigid 
dialysis schedule. Therefore, most authorities favor 
transplantation as a mode of therapy in the young.5 
On the other hand, older individuals with a well-
established, stable lifestyle may prefer not to run the 
risk of the lost time from work and the potential 
complications of transplantation . The patient's psy-
chological state also may be of importance in select-
ing a mode of therapy. Some older patients, like the 
children, may find the confining life of the dialysis 
patient to be more than they can tolerate and be 
willing to risk the uncertainties of cadaver trans-
plantation. 
The presence of complicating medical disorders 
may influence the type of management selected . Dia-
betics may fare better with transplantation because 
progression of atherosclerotic vascular disease and 
retinopathy may be less rapid than on dialysis. 5 Pa-
tients with certain enzyme defects such as Fabrey 
disease may also benefit from transplantation be-
cause the transplanted organ may serve as a source of 
the defective enzyme.6 On the other hand, trans-
plantation is contraindicated in patients with anti-
basement membrane antibody nephritis with circulat-
ing antibodies7 and in patients with large quantities 
of circulating cytotoxic antibodies7 because of the 
likelihood of rapid graft destruction after trans-
plantation. Additionally, the immunosuppressive 
medication given to patients may allow for enhanced 
tumor growth, and most surgeons will not consider 
performing transplantation in a patient with a history 
of malignancy unless there is clear evidence that the 
patient has been tumor-free for at least one year.7 The 
presence of lower urinary tract dysfunction and an 
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inadequate bladder are still considered relatively 
strong contraindications to transplantation. 
Having decided that a patient's life will be sus-
tained, a decision must be made about the form of 
dialysis to be instituted. Although chronic peritoneal 
dialysis has been an effective modality in some 
hands,8 most authorities consider it to be less desir-
able than chronic hemodialysis, and the remainder of 
this discussion will be concerned with hemodialysis. 
Two types of vascular access are available for 
connecting the patient to a dialysis machine. These 
are the silastic, external arteriovenous (AV) shunt9 
which protrudes through the skin and the internal 
AV fistula communication, using the patient's own 
vessels 10 or a foreign graft material. 11 The latter lies 
immediately under the skin and must be punctured 
with a needle at each dialysis. The fistula is preferred 
by most physicians and patients because of the free-
dom of movement and the safety which it provides. 
Where possible, it is our policy to anticipate the 
ultimate need for dialysis and to have the surgeon 
electively establish an AV fistula at about the time the 
serum creatinine reaches a concentration of8 mg/100 
ml. This allows time for maturation of the fistula 
prior to its initial use, and obviates the need for 
emergency surgery to establish vascular access in an 
ill patient. 
Hemodialysis is usually initiated in the medical 
center, but when the patient has an acceptable helper, 
every effort should be made to encourage the couple 
to learn home dialysis. The training program can be 
mastered by anyone of average intelligence and takes 
about two months to complete. As mentioned pre-
viously, patients on home dialysis have better sur-
vival statistics and are better rehabilitated. 12 
Whether dialysis is performed at home or in a 
center facility, there are a number of common com-
plications of which the physician should be aware. 
Bacterial infection of the shunt or fistula is a frequent 
problem that may lead to metastasization and re-
quires aggressive drainage and antibiotic treatment. 13 
Hepatitis B infection has been a frequent occurrence 
among dialysis patients. 14 It presents a particular 
problem in dialysis units because patients may be-
come carriers and transmit the virus to staff and other 
patients. Virtually all patients on dialysis have some 
degree of anemia.15 In the past, transfusion of poten-
tial transplant candidates was kept to a minimum 
because of possible sensitization to transplant anti-
gens. However, recent evidence suggests that frequent 
transfusions may actually enhance rather than inhibit 
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the frequency of organ acceptance. 16 Therefore, 
transfusions, particularly of saline-washed red cells, 
are now being given with less concern than in the 
past. Pericarditis continues to be a frequent and 
poorly understood complication in the dialysis pa-
tient and it does not always appear to be a manifesta-
tion of inadequate dialysis .17 Hypertension is seen 
frequently in the dialysis population ahd may be re-
lated either to expansion of the extracellular fluid 
volume or to the release of pressor substances from 
the residual damaged kidneys .18 In the latter circum-
stance, bilateral nephrectomy may produce a dra-
matic return of the blood pressure to normal. 19 Neu-
ropathy is frequently noted at the onset of dialysis 
but seldom progresses if dialysis is adequate.20 Impo-
tence is seen more frequently than not in male dialysis 
patients, and dialysis against a bath containing a high 
concentration of zinc has recently been proposed as 
effective therapy.21 As more patients are sustained 
alive for prolonged periods of time it is becoming 
clear that osteodystrophy22 and accelerated athero-
sclerosis21 are problems of great magnitude. Therapy 
of the former includes the use of oral phosphate 
binders to maintain the serum phosphorus concentra-
tion levels at normal , and a supplemental vitamin D 
preparation to enhance intestinal calcium absorption; 
there does not appear to be any effective therapy for 
the latter. 
Many of the problems mentioned above will be 
corrected by a functioning transplant. However, 
there are a number of problems which are unique to 
the transplant population. Most of the difficulties 
associated with early transplant rejection are man-
aged by the transplant team prior to discharge from 
the hospital after surgery, and these will not be con-
sidered here. Chronic rejection may occur late after 
transplantation, is characterized by a slow deteriora-
tion in function , and is generally unresponsive to 
therapy. Infection remains the major cause of mor-
bidity and mortality among transplant patients.23 Be-
cause of the constant need for immunosuppressive 
medication these patients have an increased suscepti-
bility to both common bacterial pathogens and to 
opportunistic viruses such as herpes hominis and 
cytomegalovirus; fungi such as cryptococcus and as-
pergillus; and protozoa such as pneumocystis and 
toxoplasmosis . Hypertension also is a frequent com-
plication of transplantation and may be difficult to 
control. A diabetic diathesis may be brought out by 
the administration of steroids as immunosuppressive 
agents.24 Osteoporosis may develop as a complication 
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of long-term steroid administration.24 The constant 
immunosuppression may also allow for the develop-
ment of tumor growth and there is a much higher 
incidence of malignancy in transplant patients than in 
a comparable, non-immunosuppressed population.24 
Gastrointestinal bleeding is a feared complication of 
transplantation that is frequently fatal. 24 Con-
sequently, many transplant surgeons perform pro-
phylactic gastric surgery in any potential candidate 
who has the slightest history of ulcer disease. 
It is our feeling that selection of a proper thera-
peutic modality in a patient with ESRD requires 
careful consideration of the medical, psychological, 
social, and economic aspects of the patieht's illness. 
His needs may change through the course of illness 
and, as a consequence, the ESRD prescription may 
require alteration. Thus, a patient might initially be 
managed with home dialysis, receive a living related 
donor transplant after a sibling decided to become a 
donor, and return to home dialysis after rejection 
occurred. 
The economic costs of ESRD treatment are stag-
gering. 25 At present there are more than 37,000 indi-
viduals receiving some type of ESRD therapy in the 
United States at an annual cost of $902 million. By 
1982 it is projected that the cost for 55,900 patients 
will be 2.3 billion . Most patients are eligible for finan-
cial coverage of the major portion of their dialysis or 
transplantation cost either via private insurance car-
rier, Medicare, or the Veterans Administration. At 
present the annual cost of in-center dialysis is approx-
imately $23,400 while that of home dialysis is 
$12,480. The initial cost of hospitalization for trans-
plant surgery is about $17,000. These estimates do 
not include the cost of hospitalization for various 
complications of either the dialysis or transplant 
state; and, as suggested earlier, these may be formi-
dable. 
In the future, dialysis equipment may be made 
more compact and a satisfactory portable dialyzer 
may q_e developed. The use of sorbent materials may 
allow dialysis with small quantities of fluid, and high 
potency antithymocyte globulin may improve the 
early survival of cadaver grafts. Techniques also may 
be developed for the stimulation of blocking anti-
bodies in the recipient which will allow for improved 
graft survival with lower doses of immunosuppressive 
drugs. However, none of these innovations seem 
likely to dramatically change the management of 
ESRD in the near future. 
The management of ESRD has been briefly re-
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viewed; both dialysis and transplantation are useful 
modalities of therapy and are not mutually exclusive. 
Management in a giv'en patient should be designed to 
best meet his medical, psychological, social, and eco-
nomic needs. 
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